Erasca (ERAS) Interest Expenses (2020 - 2025)
Erasca posted quarterly Interest Expenses of $81000.0 for Q2 2025, down 82.39% year-on-year from $460000.0 in Q2 2024, and up 6.58% on a QoQ basis from $76000.0 in Q1 2025.
Erasca (ERAS) has 6 years of Interest Expenses data on file, last reported at $81000.0 in Q2 2025.
- For the quarter ending Q2 2025, Interest Expenses fell 82.39% year-over-year to $81000.0; the trailing twelve-month figure through Mar 2026 stood at $81000.0 (down 84.89% YoY), and the FY2025 full-year result was $248000.0, down 88.5% from the prior year.
- Interest Expenses for Q2 2025 stood at $81000.0, up from $76000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $460000.0 in Q2 2024 and bottomed at $49000.0 in Q3 2022.
- The 5-year median for Interest Expenses is $66000.0 (2024), against an average of $90600.0.
- The widest annual swing landed in 2024, when Interest Expenses soared 641.94%; it then sank 82.39% in 2025.
- A 5-year view of Interest Expenses shows it stood at $74000.0 in 2021, then slumped by 32.43% to $50000.0 in 2022, then jumped by 34.0% to $67000.0 in 2023, then jumped by 586.57% to $460000.0 in 2024, then tumbled by 82.39% to $81000.0 in 2025.
- The last three Interest Expenses figures came in at $81000.0 (Q2 2025), $76000.0 (Q1 2025), and $460000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Jun 30, 2024 | 460,000.00 |
| Jun 30, 2024 | 460,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Dec 31, 2023 | 67,000.00 |
| Dec 31, 2023 | 67,000.00 |
| Sep 30, 2023 | 49,000.00 |
| Sep 30, 2023 | 49,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Mar 31, 2023 | 51,000.00 |
| Mar 31, 2023 | 51,000.00 |
| Dec 31, 2022 | 50,000.00 |
| Dec 31, 2022 | 50,000.00 |
| Sep 30, 2022 | 49,000.00 |
| Sep 30, 2022 | 49,000.00 |
| Jun 30, 2022 | 91,000.00 |
| Jun 30, 2022 | 91,000.00 |
| Mar 31, 2022 | 67,000.00 |
| Mar 31, 2022 | 67,000.00 |
| Sep 30, 2021 | 74,000.00 |
| Sep 30, 2021 | 74,000.00 |
| Jun 30, 2021 | 61,000.00 |
| Jun 30, 2021 | 61,000.00 |
| Mar 31, 2021 | 55,000.00 |
| Mar 31, 2021 | 55,000.00 |
| Sep 30, 2020 | 38,000.00 |
| Sep 30, 2020 | 38,000.00 |
| Jun 30, 2020 | 33,000.00 |
| Jun 30, 2020 | 33,000.00 |